KLSE (MYR): DCHCARE (0283)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.165
Today's Change
0.00 (0.00%)
Day's Change
0.165 - 0.165
Trading Volume
176,200
Market Cap
164 Million
NOSH
996 Million
Latest Quarter
30-Jun-2024 [#2]
Announcement Date
27-Aug-2024
Next Quarter
30-Sep-2024
Est. Ann. Date
30-Nov-2024
Est. Ann. Due Date
29-Nov-2024
QoQ | YoY
15.15% | -267.06%
Revenue | NP to SH
56,421.000 | -18,434.000
RPS | P/RPS
5.66 Cent | 2.91
EPS | P/E | EY
-1.85 Cent | -8.92 | -11.21%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.05 | 3.30
QoQ | YoY
-139.22% | -389.21%
NP Margin | ROE
-32.67% | -37.00%
F.Y. | Ann. Date
30-Jun-2024 | 27-Aug-2024
Latest Audited Result
31-Dec-2023
Announcement Date
30-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
30-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Revenue | NP to SH
67,789.000 | 2,560.000
RPS | P/RPS
6.80 Cent | 2.43
EPS | P/E | EY
0.26 Cent | 64.21 | 1.56%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.06 | 2.75
YoY
null%
NP Margin | ROE
3.78% | 4.28%
F.Y. | Ann. Date
31-Dec-2023 | 27-Feb-2024
Revenue | NP to SH
46,670.000 | -29,240.000
RPS | P/RPS
4.68 Cent | 3.52
EPS | P/E | EY
-2.94 Cent | -5.62 | -17.79%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
7.57% | -329.37%
NP Margin | ROE
-62.65% | -58.70%
F.Y. | Ann. Date
30-Jun-2024 | 27-Aug-2024
Trailing 4 Quarters | Trailing 8 Quarters | |||
---|---|---|---|---|
Available Quarters | 4 Quarters | 8 Quarters | ||
Continuous Quarters Of Revenue Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Total Positive Profit Years | 0 / 4 | 0.00% | 2 / 8 | 25.00% |
Continuous Quarters Of Positive Profit | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Profit Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Continuous Quarters Of Adjusted EPS Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Total Dividend Years | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Average ROE | -8.11% | -0.10% | ||
Average Net Profit Margin | -38.95% | -14.92% |
Last 5 Financial Years | Last 10 Financial Years | |||
---|---|---|---|---|
Available Years | 5 Years | 10 Years | ||
Continuous Quarters Of Revenue Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Total Positive Profit Years | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Positive Profit | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Profit Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Adjusted EPS Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Total Dividend Years | 0 / 2 | 0.00% | 0 / 2 | 0.00% |
Continuous Quarters Of Dividend | 0 / 2 | 0.00% | 0 / 2 | 0.00% |
Continuous Quarters Of Dividend Growth | 0 / 2 | 0.00% | 0 / 2 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 0 / 2 | 0.00% | 0 / 2 | 0.00% |
Average ROE | 2.14% | 2.14% | ||
Average Net Profit Margin | 1.89% | 1.89% |
T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
---|---|---|---|---|---|
Revenue | 56,421 | 46,670 | 67,789 | 33,894 | 33,894 |
NP to SH | -18,434 | -29,240 | 2,560 | 1,280 | 1,280 |
Dividend | 0 | 0 | 0 | 0 | 0 |
Adjusted EPS | -1.85 | -2.94 | 0.26 | 0.13 | 0.13 |
Adjusted DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
---|---|---|---|---|---|
Revenue | 46.83% | -22.42% | -32.76% | -1.59% | 21.86% |
NP to Owner | 15.15% | -267.06% | -329.37% | -45.62% | -345.17% |
Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Adjusted EPS | 15.19% | -266.17% | -329.77% | -44.86% | -342.89% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
---|---|---|---|---|---|---|---|---|---|
Revenue | -16.77% | 66.46% | 66.46% | -31.15% | 37.69% | 37.69% | 0.00% | 100.00% | 100.00% |
NP to Owner | -820.08% | -1,540.16% | -1,540.16% | -1,242.19% | -2,384.38% | -2,384.38% | 0.00% | 100.00% | 100.00% |
Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Adjusted EPS | -811.54% | -1,523.08% | -1,523.08% | -1,230.77% | -2,361.54% | -2,361.54% | 0.00% | 100.00% | 100.00% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Wow, DC Healthcare has been acknowledged in Malaysia Book of Records for being the first aesthetic clinic chain listed on Bursa Malaysia's ACE Market
https://www.nst.com.my/business/corporate/2024/09/1104776/dc-healthcare-recognised-being-ace-markets-first-aesthetic-clinic
2 months ago
all clear at 165, once new shop will start operating at q3 & can start to see some profit this quarter
2 months ago
The company will ensure that aesthetic healthcare is not just a service, but a necessity for enhancing wellbeing. Vry nice ~
2 months ago
Yupe, buying volume is slowly increasing and it will break through 20 cents eventually
2 months ago
Now this company has become very famous among Malaysians because of the advertisements they have done
1 month ago
Surface advertising only. Internal a lot of problems. Even their interviews are low standard, main problem many patients went to other aesthetic clinic, and complain Dr Chong quality, rather burn their left over package than going back. This is so bad
1 month ago
Yes. Saw all these naive comments without facts or research. Cannot tahan joined and gave my view. That’s called keyboard warrior FetcoveXX?
1 month ago
Jimmy7890 is from another aesthetic clinic which is not recognized by the Malaysia Book of Records ? 🤔 Why so jealous of DC healthcare getting interviewed?
1 month ago
hahaha sour comment spotted! DCHCARE doubling down on penang healthcare hub/tourism, see you above 0.20 soon
1 month ago
How can investors believe that after just one year the price fell cheaper than the IPO price?
Dr Chong pun cong jugak ke?
🤔🤔🤔
1 month ago
The company may use the funds saved from cancelling the RM70 million acquisition of I Bella Sdn Bhd for share buybacks 😁
1 month ago
@Travisbravis
big announcement soon, dr chong wont let us down
@marcelle5
Dr chong will push the share price up lah, ez tp 0.20
.........................................................................................................
Just after 1 year the market share price felt below IPO price..
also the technical chart stick all negative shown STRONG SELLLLLLLLLL...
All in just 1 yearrrrrrr...
huhuhuhu
1 month ago
Traders are often short-sighted. Look at Gen Z nowadays, the aesthetic industry is definitely booming
1 month ago
The new year is coming. People will go to the clinic to redeem aesthetic services 😁
1 month ago
Oops, still not 20cents yet, dropped further from my last comment. Good luck to Dr Chong paid fan 😄
1 month ago
Dow Jones
Dow Jones Industrial Average
42,740.42
-324.80
0.75%
Nasdaq
NASDAQ Composite
18,315.58
-187.10
1.01%
1 month ago
Target Price: RM0.200, RM0.220
Last closing price: RM0.180
Potential return: 11.1%, 22.2%
Support: RM0.175
Stop Loss: RM0.150
Huhuhuu
Still below IPO price..
4 weeks ago
Dow member McDonald’s
closed more than 5% lower. The Centers for Disease Control and Prevention said late Tuesday that an E. coli outbreak tied to the fast-food giant’s Quarter Pounder burgers has resulted in 10 hospitalizations and one death.
4 weeks ago
New IPO coming similar to DCHCARE..
METRO HEALTHCARE BERHD..
Same IPO price with DCH..
Going down also like DCH..
Huhuhu
2 weeks ago
DC Healthcare Holdings Berhad, has been actively expanding its operations by opening new branches across Malaysia. Their aggressive growth strategy has led to increased administrative and advertising expenses, contributing to recent financial losses. For instance, in the fourth quarter ended December 31, 2023, the company reported a net loss of RM1.07 million, despite achieving a revenue of RM17.57 million.
The share price has experienced a significant decline, closing at RM0.16 on November 8, 2024, marking a 69.23% drop over the past year. This downturn can be attributed to the financial losses and market concerns regarding the sustainability of its rapid expansion.
But I think the company's strategic initiatives, such as the establishment of new clinics in key locations like Johor Bahru and Ipoh, aim to tap into high-income markets and drive future revenue growth. Additionally, the implementation of an Employee Share Option Scheme (ESOS) is intended to align employee interests with company performance, potentially enhancing operational efficiency and profitability.
And I think, the share price may remain under pressure in the short term due to ongoing financial challenges and market scepticism. However, if the company's expansion efforts lead to increased market share and profitability, and if the ESOS successfully motivates employees to drive performance, there is potential for share price recovery in the medium to long term.
I think this will rebound sooner than later by 2nd Quarter 2025
1 week ago
Since its listing on Bursa, DCHCARE has encountered considerable financial challenges, reporting a net loss of RM18.49 million over the past twelve months and maintaining a negative profit margin of 32.82%. The stock has exhibited marked volatility, with weekly fluctuations averaging 10%, placing it among the top 25% of the most volatile stocks on the Malaysian market.
I believe the company’s strategy to expand its aesthetic services footprint—from 12 outlets in Q2 2023 to 17 in Q2 2024—alongside the launch of new product lines under the Ten Doctors brand and four additional outlets dedicated to slimming services, shows a strong commitment to growth. This increase, bringing the total to 21 outlets in Q2 2024 compared to the previous year’s 12, could create favourable prospects for financial recovery. However, the success of these initiatives will likely depend on broader market conditions and prevailing investor sentiment.
1 week ago
Trianon
Have show at the end of this year because DC Healthcare will expand its business to Sabah and Sarawak by the end of this year
2 months ago